Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Chang Moo Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5382-4658; OpenAlex author ID A5025462310, A5032951526, A5064124768. Sources: OpenAlex.

Their work

Papers
98 (first author 13, last author 34)
Trials
0
Grants
0
Labs led
1
Collaborators
152
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 6 papers · 2014: 7 papers · 2015: 2 papers · 2016: 6 papers · 2017: 6 papers · 2018: 4 papers · 2019: 6 papers · 2020: 14 papers · 2021: 11 papers · 2022: 10 papers · 2023: 4 papers · 2024: 7 papers · 2025: 6 papers · 2026: 5 papers

Papers 50 of 98

  1. Cardiovascular-Kidney-Metabolic Syndrome Severity and Risk of Pancreatic Cancer in a Large Prospective Cohort. Last author DOI 10.1002/dmrr.70214↗
  2. Comparison of Long-Term Oncologic and Perioperative Outcomes of Minimally Invasive and Open Pancreatoduodenectomy for Resectable and Borderline Resectable Panc… Last author DOI 10.1002/jhbp.70063↗
  3. Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort study. Last author DOI 10.1007/s00464-026-12646-3↗
  4. Minimally Invasive Pancreatoduodenectomy for Pancreatic Cancer: Current Perspectives and Future Directions. First author DOI 10.3390/cancers18020197↗
  5. Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future u… Co-author DOI 10.4174/astr.2026.110.2.76↗
  6. Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cance… Last author DOI 10.1177/15347354251353499↗
  7. Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Curative Surgery. Co-author DOI 10.1245/s10434-025-18029-7↗
  8. Laparoscopic omentopexy as a spacer for carbon-ion radiotherapy in locally advanced pancreatic cancer. Last author DOI 10.14701/ahbps.25-044↗
  9. Is There a Potential Oncologic Role for Local Therapy on Hepatic Metastasis in Patients Who Undergo Curative Pancreatectomy for Pancreatic Cancer? Last author DOI 10.3349/ymj.2024.0078↗
  10. Immediate Postoperative AbnobaVISCUM® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic Cancer Resection. Last author DOI 10.3349/ymj.2024.0493↗
  11. Stromal secreted protein acidic and rich in cysteine expression: A potential target for improved prognosis in patients with pancreatic cancer. Last author DOI 10.4251/wjgo.v17.i11.110704↗
  12. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
  13. Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancreatic Cancer. Co-author DOI 10.1021/acs.jproteome.3c00695↗
  14. Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer. Co-author DOI 10.1186/s12967-024-05181-z↗
  15. Port-site metastasis after laparoscopic radical pancreatosplenectomy in left-sided pancreatic cancer. Last author DOI 10.14701/ahbps.23-092↗
  16. Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer. Co-author DOI 10.3349/ymj.2023.0399↗
  17. Glucose-to-Lymphocyte Ratio (GLR) as an Independent Prognostic Factor in Patients with Resected Pancreatic Ductal Adenocarcinoma-Cohort Study. Last author DOI 10.3390/cancers16101844↗
  18. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy. Co-author DOI 10.4143/crt.2023.586↗
  19. Development of a metabolite calculator for diagnosis of pancreatic cancer. Last author DOI 10.1002/cam4.6233↗
  20. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  21. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  22. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  23. Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1025↗
  24. Comparison of oncologic outcomes between open and laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma using data from the KOTUS-BP national… Co-author DOI 10.1016/j.hpb.2022.01.012↗
  25. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. Last author DOI 10.1016/j.pan.2022.08.009↗
  26. Anticancer effect of locally applicable aptamer-conjugated gemcitabine-loaded atelocollagen patch in pancreatic cancer patient-derived xenograft models. Last author DOI 10.1111/cas.15318↗
  27. Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer. Last author DOI 10.1159/000525294↗
  28. Laparoscopic radical distal pancreatosplenectomy with celiac axis excision following neoadjuvant chemotherapy for locally advanced pancreatic cancer. Last author DOI 10.14701/ahbps.21-097↗
  29. Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches Co-author DOI 10.14701/ahbps.22-009↗
  30. Laparoscopic distal pancreatosplenectomy for left-sided pancreatic cancer in patients with radical subtotal gastrectomy for gastric cancer. Last author DOI 10.14701/ahbps.22-016↗
  31. Should the Splenic Vein Be Preserved-Fate of Sinistral Portal Hypertension after Pancreatoduodenectomy with Vascular Re-Section for Pancreatic Cancer. Last author DOI 10.3390/cancers14194853↗
  32. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  33. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer. Last author DOI 10.1007/s13402-021-00643-8↗
  34. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  35. Usefulness of artificial intelligence for predicting recurrence following surgery for pancreatic cancer: Retrospective cohort study. Co-author DOI 10.1016/j.ijsu.2021.106050↗
  36. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. Last author DOI 10.1016/j.pan.2021.02.007↗
  37. Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. Co-author DOI 10.1021/acs.jproteome.1c00805↗
  38. Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. Co-author DOI 10.1177/0284185120917118↗
  39. Complete response of locally advanced left-sided pancreatic cancer after modified FOLFIRINOX chemotherapy followed by conversion surgery: A case report. Last author DOI 10.14701/ahbps.2021.25.3.390↗
  40. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  41. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  42. What Is the Next in Developing Model to Predict Survival Outcomes of Resected Pancreatic Cancer? Co-author DOI 10.5009/gnl210503↗
  43. Laparoscopic pancreaticoduodenectomy in pancreatic ductal adenocarcinoma. Last author DOI 10.7602/jmis.2021.24.3.169↗
  44. Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy. Last author DOI 10.1016/j.pan.2019.12.006↗
  45. Oncologic Impact of Local Recurrence in Resected Pancreatic Cancer and Topographic Preference in Local Recurrence Patterns According to Tumor Location. Co-author DOI 10.1097/mpa.0000000000001679↗
  46. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  47. Feasibility and Safety of Laparoscopic Radical Distal Pancreatosplenectomy with Adrenalectomy in Advanced Pancreatic Cancer. Last author DOI 10.1245/s10434-020-08670-9↗
  48. ASO Author Reflections: From Concept to Real Clinical Practice of Laparoscopic Distal Pancreatectomy for Left-Sided Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08676-3↗
  49. Laparoscopic repeated pancreatectomy for isolated local recurrence in remnant pancreas following laparoscopic radical pancreatectomy for pancreatic ductal aden… Last author DOI 10.14701/ahbps.2020.24.4.542↗
  50. Neoadjuvant chemotherapy followed by total pancreatectomy with splenectomy and combined vascular resections after preoperative percutaneous transhepatic portal… Last author DOI 10.14701/ahbps.2020.24.4.551↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ho Kyoung Hwang · 62 shared papers, 2012–2026 · strength 8.89
  2. Woo Jung Lee · 55 shared papers, 2011–2025 · strength 6.03
  3. Sung Hyun Kim · 19 shared papers, 2016–2026 · strength 4.22
  4. Seung Soo Hong · 11 shared papers, 2020–2026 · strength 2.80
  5. Munseok Choi · 11 shared papers, 2020–2026 · strength 2.79
  6. Sung Hwan Lee · 17 shared papers, 2014–2024 · strength 1.94
  7. Jin Seok Heo · 11 shared papers, 2017–2026 · strength 1.41
  8. Seoung Yoon Rho · 7 shared papers, 2018–2026 · strength 1.26
  9. Seungmin Bang · 11 shared papers, 2013–2024 · strength 1.20
  10. Jeong Youp Park · 11 shared papers, 2012–2024 · strength 1.11
  11. Hongbeom Kim · 7 shared papers, 2020–2026 · strength 1.05
  12. Moon Jae Chung · 8 shared papers, 2013–2025 · strength 1.01
  13. Jin‐Young Jang · 10 shared papers, 2017–2023 · strength 0.98
  14. In Woong Han · 5 shared papers, 2020–2026 · strength 0.85
  15. Wooil Kwon · 8 shared papers, 2017–2023 · strength 0.78
  16. Mi‐Suk Park · 5 shared papers, 2019–2024 · strength 0.74
  17. Song Cheol Kim · 7 shared papers, 2018–2023 · strength 0.70
  18. Min Jung Lee · 5 shared papers, 2019–2024 · strength 0.70
  19. Young‐Ki Paik · 5 shared papers, 2019–2024 · strength 0.70
  20. Seung‐seob Kim · 4 shared papers, 2022–2024 · strength 0.70
  21. Si Young Song · 11 shared papers, 2012–2022 · strength 0.67
  22. Jae Uk Chong · 5 shared papers, 2017–2025 · strength 0.65
  23. Choong‐kun Lee · 4 shared papers, 2021–2024 · strength 0.65
  24. Hee Seung Lee · 5 shared papers, 2020–2024 · strength 0.63
  25. Seungyeoun Lee · 7 shared papers, 2017–2023 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.